Femasys Inc.
FEMY
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $9.0M
$2.98
▼ -2.61%
P/E
-2.22
Mkt Cap
$9.0M
52-Wk Range
$2.02–$22.20
52-Week Range
$2.02 - $22.20
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 61.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary non-surgical medical device technology
- FDA regulatory clearances and intellectual property protections
- Strong positioning in underserved women's healthcare market
- Direct relationships with obstetric-gynecological physician networks
Bear Case
1 risk
- Low volatility (beta -2.1).
Growth
Moderate growth ahead
Expanded adoption of FemVue across US and international markets
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Falling
-44.7% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying FEMY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 17, 2026
AUG 14, 2026
Reported EPS of -$1.33 vs -$1.31 consensus (-1.5% surprise). Revenue of $331.8K vs $730.7K expected (-54.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.5%
Revenue trend · last 8Q
—
—
+26%
+85%
+31%
+40%
+25%
-19%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$554.9K
$581.6K
$341.3K
$409.3K
$729.4K
$813.4K
$424.9K
$331.8K
Margins · last 8Q
Gross
-19.8%
Profit
-1190.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How FEMY stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related